Roy Fleischmann
Dallas, TXNPI 1467451146
Payments from drug & device makers
Across 1,583 payments — averaging $2385.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1.1M
- UCB SA$524K
- Eli Lilly$340K
- Amgen$266K
- E.r. Squibb & Sons, L.L.C.$246K
- Pfizer$228K
- plus $1.1M from 33 others
Across 73 payments — averaging $1190.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$52K
- AbbVie$15K
- Sanofi-aventis U.S. LLC$9K
- Eli Lilly$5K
- Sanofi$5K
- GSK$254
What the payments were for
- Consulting fees$649,48162%
- Speaking & faculty fees$271,72326%
- Grants$25,0002%
- Travel & lodging$89,4419%
- Food & beverage$11,0781%
- Education$1640%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 545 | $1,060,786 |
| UCB SA | 73 | $523,715 |
| Eli Lilly | 92 | $340,115 |
| Amgen(2 entities) | 15 | $266,123 |
| E.r. Squibb & Sons, L.L.C. | 81 | $246,017 |
| Pfizer | 148 | $228,056 |
| GSK | 143 | $225,469 |
| Regeneron | 18 | $197,679 |
| EMD Serono, Inc. | 34 | $176,475 |
| UCB, Inc. | 1 | $88,036 |
| Teva Pharmaceuticals USA, Inc. | 26 | $77,798 |
| Genentech, Inc. | 35 | $73,764 |
| Gilead | 27 | $69,593 |
| Novartis | 93 | $41,829 |
| Janssen Scientific Affairs, LLC | 140 | $31,828 |
| Lilly USA, LLC | 16 | $23,333 |
| UCB GmbH | 2 | $20,438 |
| Janssen Research & Development, LLC | 2 | $16,800 |
| Boehringer Ingelheim | 13 | $14,190 |
| Whitehall International Inc | 1 | $8,500 |
| Merck | 10 | $8,332 |
| Daiichi Sankyo Company LTD | 1 | $7,500 |
| Pfizer Chile S.A. | 1 | $6,300 |
| Sanofi US Services Inc. | 3 | $5,259 |
| Sanofi | 20 | $4,136 |
| Eisai Inc. | 1 | $2,000 |
| Mylan Inc. | 1 | $1,953 |
| Genentech USA, Inc. | 9 | $1,705 |
| Celltrion, Inc. | 1 | $1,650 |
| Almirall LLC | 1 | $1,600 |
| Daiichi Sankyo Inc. | 20 | $1,221 |
| Samsung Bioepis Co., Ltd. | 1 | $800 |
| Roche Products Limited | 1 | $800 |
| Galderma Laboratories, L.p. | 1 | $800 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $600 |
| Celltrion Healthcare Co., Ltd | 1 | $600 |
| Assertio Therapeutics, Inc. | 2 | $475 |
| AstraZeneca | 1 | $62 |
| Aurinia Pharma U.S., Inc. | 2 | $50 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.